Vitamin D in Rheumatic Disease - Is It Good Enough? Vitamin D in rheumatic disease — is it sufficient? Vitamin D deficiency/insufficiency is common and linked to inflammatory rheumatic diseases, raising the question of whether low vitamin D drives immune dysregulation, disease https://t.co/Xd8s8LKqKT

Parvovirus B19 Infection - Images from JAMA Dermatology. 40yoM 2-days asymptomatic rash w/ fever to 39°C, w/ arthralgias, Rash on BL cheeks, inguinal, flanks, axilla. WBC =2K, CRP 1.24 mg/dl. Dx by PCR for parvovirus B19 DNA https://t.co/LGGnabvFvA https://t.co/XzPlaWkIfz

Applying updated ACR guidelines in real life isn’t always straightforward. Two experts share insights on managing lupus nephritis beyond the textbook. Sponsored by Aurinia https://t.co/Zfu8ij8DNe https://t.co/nFVJenDkqc

An IL-23i through ~5 years: How did clinical manifestations of PsA and radiographic progression change during long-term treatment? 🔥View the latest long-term data from ACR to find out more. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/zXHqLw5mTI https://t.co/uMr6kcTXkz

Meet the RheumNow #EULAR2026 Reporting Team Delivering real-time insights from the forefront of rheumatology: 🩺 Dr. Antoni Chan (@synovialjoints) 🩺 Dr. Mrinalini Dey (@DrMiniDey) 🩺 Dr. Jiha Lee (@JihaRheum) 🩺 Dr. Aurelie Najm (@AurelieRheumo) 🩺 Dr. Janet Pope https://t.co/zpIeGWpL6P

Toll-Like Receptor Drugs Effective in Cutaneous Lupus Enpatoran, an investigational oral drug that inhibits Toll-like receptors (TLR) 7 and 8, was superior to placebo in relieving lupus skin manifestations in a dose-finding phase II trial. https://t.co/R1wbJHXwjD https://t.co/65HtG0Te94

Lupus Mortality Risk in Young Women New research using death certificate data from 52,942 females, reveals that systemic lupus erythematosus (lupus) is a leading cause of years of potential life lost among young women in the United States, underscoring the disease’s significant https://t.co/2FSINr6gZN

Branebrutinib (Bruton's tyrosine kinase inhibitor) was studied in phase 2 RCT of 85 RA pts for 12 weeks and was safe but failed to achieve an ACR50 response (19% BTK vs 33% PBO; p=0·16). https://t.co/gTjLJm9iIW https://t.co/GN9p1P8ZNJ

RA adds to mortality risk in nontuberculous mycobact. infx (NTM). Retro study 1420 NTM pts, 66 (4.6) had RA. RA was independent predictor of resp-death (HR 4.30) - partly explained by ILD & systemic inflammation https://t.co/S9bndHsXCE https://t.co/mC74Qve1LZ

NEJM reports a 10 yrs study of Arthroscopic Partial Meniscectomy (APM) for Degenerative Tear — randomized, sham-surgery–controlled RCT of 147 pts w/o Knee https://t.co/WMGRIOunwZ 10 years, found no signif benefit betw APM and Sham surgery (pain, function) & possible worsening https://t.co/979C7IYuyZ

UCB has aquired Candid Therapeutics for $2 billion; plan to lead in autoimmune dz by acquiring cizutamig - a T cell engager. Its been studied in >100 pts, including early Global Phase 2 RCTs of myasthenia gravis & ILD. https://t.co/xz4uEhvxu6 https://t.co/6FS1riLecW

ArthritisPower Registry (now PatientSpot) survey study of 351 RA pts (age 60, F 84%); reported 439 nonserious infx. 27% total infx, 14%w/ MD visist & Abx. Infx incr w/ GC ≥10 mg/d (OR 1.94), but Biologics & JAKi not assoc. w/ greater NSIE risk vs cs DMARDs https://t.co/bHqFnoY0Ud